Aroa Biosurgery Study Backs Efficacy and Cost Edge of Myriad Trauma Scaffold

Aroa Biosurgery Ltd ( (AU:ARX) ) has issued an announcement.

Aroa Biosurgery announced new interim data from its large, ongoing MASTRR registry showing that its Myriad Matrix and Myriad Morcells ovine-ECM bioscaffolds delivered effective and economical treatment of complex trauma and acute care surgery wounds. In 49 patients with 61 challenging, often contaminated defects treated across four US Level I trauma centres, wounds achieved full vascularised tissue coverage in a median of 22.5 days, typically after a single application and with no device-related complications, while cost comparisons against other bioscaffolds indicated Myriad is cheaper per centimetre with equivalent or superior key outcomes. Management and participating surgeons said the findings validate Myriad as a cost‑effective option that can lower total hospital care costs, reinforcing Aroa’s evidence base—now exceeding 116 peer‑reviewed studies—and highlighting a US trauma surgery market opportunity of roughly US$450 million that the company views as a strategic growth focus.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

More about Aroa Biosurgery Ltd

Aroa Biosurgery is a New Zealand–headquartered soft‑tissue regeneration company that develops, manufactures and distributes medical and surgical products for complex wound healing and soft tissue reconstruction. Its portfolio is based on the proprietary AROA ECM extracellular matrix bioscaffold derived from ovine forestomach, with more than 7 million products used globally and a primary commercial focus on the US market through its direct sales force and partner TELA Bio. Listed on the ASX, Aroa targets high-value reconstructive and trauma indications where its biomaterials can improve clinical outcomes and reduce costs.

Average Trading Volume: 263,867

Technical Sentiment Signal: Buy

Current Market Cap: A$248.4M

For a thorough assessment of ARX stock, go to TipRanks’ Stock Analysis page.